DOCSLIB.ORG

Comments & Controversies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comments & Controversies Comments & Controversies Hallucinogen sequelae Common visual disturbances attributed I appreciated “The woman who saw the to HPPD are recurrent geometric halluci- light” (C!""#$% P&'()*+%"', July 2010, nations, perception of peripheral move- p. 44-48) in which Dr. R. Andrew ment, colored "ashes, intensi#ed colors, Sewell et al describe a 30-year-old palinopsia, positive afterimages, haloes woman with schizoaffective disorder around objects, macropsia, and micropsia and a 7-year history of visual distur- occurring spontaneously in individuals bances, including “,ashing lights.” with no prior psychopathology. These dis- The authors’ differential diagnosis did turbances can be intermittent or continu- not include the possibility of visual ous, slowly reversible or irreversible, but disturbance secondary to atypical anti- are severe, intrusive, and cause functional psychotic serotonergic antagonism. debility. Su!erers retain insight that these Photopsia and similar phenomena are phenomena are the consequence of LSD not uncommon with 5HT antagonist use and usually seek psychiatric help. 1 antidepressants, such as nefazodone. July 2010 HPPD may be diagnosed by the pres- They also are well-known sequelae ence of an identi#able trigger, prodromal of lysergic acid diethylamide (LSD), a symptoms, and presentation onset; by the VA: American Psychiatric Publishing, Inc.; 2007. complex serotonin antagonist/agonist, 2. Kranzler H, Ciraulo D. Clinical manual of addiction characteristics of the perceptual distur- psychopharmacology. Arlington, VA: American and would be included under the Psychiatric Publishing, Inc.; 2005. bances, their frequency, duration, intensi- DSM-IV-TR diagnosis hallucino- 3. Halpern JH, Pope HG Jr. Hallucinogen persisting ty, and course; and by the accompanying perception disorder: what do we know after 50 2 gen persisting perceptual disorder years? Drug Alcohol Depend. 2003;69:109-119. negative a!ect and preserved insight. (HPPD).2 Risperidone, a 5HT2-block- 4. Abraham HD, Mamen A. LSD-like panic from This LSD-induced persistence of visual risperidone in post-LSD visual disorder. J Clin ing atypical, and selective serotonin Psychopharmacol. 1996;16(3):238-241. imagery after the image is removed from reuptake inhibitors may worsen HPPD 5. Lauterbach EC, Abdelhamid A, Annandale JB. the visual #eld is thought to result from Posthallucinogen-like visual illusions (palinopsia) effects.3,4 Visual disturbance with ris- with risperidone in a patient without previous dysfunction of serotonergic cortical inhibi- hallucinogen exposure: possible relation to serotonin peridone also has been reported in a 5HT2a receptor blockade. Pharmacopsychiatry. tory interneurons with GABAergic outputs 2000;33(1):38-41. patient with no LSD exposure.5 Dr. that normally suppress visual processors.3 Sewell’s patient was treated sequential- Clonazepam often is helpful.2 ly with aripiprazole and olanzapine. The authors respond R. Andrew Sewell, MD Both have 5HT blocking properties. We agree with Dr. Krasnow that HPPD be- VA Connecticut Healthcare/Yale University School of Medicine I wonder if the patient has a history longs within our di!erential diagnosis for New Haven, CT of hallucinogen or LSD exposure, or photopsia and regret omitting it from our David Kozin whether her visual symptoms might article. We consider this to be unlikely, how- McLean Hospital/Harvard Medical School be related to the use of atypical anti- ever, because she had no prior LSD use, a Belmont, MA psychotics combined with sertraline. history of well-formed visual hallucinations Miles G. Cunningham, MD, PhD McLean Hospital/Harvard Medical School It would be interesting to see if her not characteristic of HPPD, and no other Belmont, MA symptoms abated with use of a -rst- characteristic symptoms of HPPD (palinop- generation antipsychotic. sia, afterimages, illusory movement, etc.). References 1. Espiard ML, Lecardeur L, Abadie P, et al. Charles Krasnow, MD In addition, she tolerated olanzapine Hallucinogen persisting perception disorder Adjunct clinical assistant professor of well, and there is anecdotal evidence and after psilocybin consumption: a case study. Eur psychiatry Psychiatry. 2005;20:458-460. 1 case report to suggest that olanzapine 2. Lerner AG, Gelkopf M, Skladman I, et al. University of Michigan Medical School Clonazepam treatment of lysergic acid Ann Arbor, MI exacerbates HPPD.1 diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int HPPD typically is considered a rare Clin Psychopharmacol. 2003;18:101-105. References sequela of LSD use, although even more 3. Abraham HD, Aldridge AM. Adverse 1. Schatzberg A, Cole J, DeBattista DMH. Manual of consequences of lysergic acid diethylamide. clinical psychopharmacology. 6th ed. Arlington, rarely it may be caused by other drugs. Addiction. 1993;88:1327-1334. To comment on articles in this issue or other topics, send letters in care of Christina Thomas, Current Psychiatry Vol. 9, No. 9 5 CURRENT PSYCHIATRY, 7 Century Drive, Suite 302, Parsippany, NJ 07054, [email protected] or visit CurrentPsychiatry.com and click on the “Send Letters” link..
Load more

Recommended publications
  • Aripiprazole As an Adjunct to Anti-Depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-Effectiveness, and Guidelines
    TITLE: Aripiprazole as an Adjunct to Anti-Depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 04 May 2016 RESEARCH QUESTIONS 1. What is the clinical efficacy of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 2. What is the cost-effectiveness of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 3. What are the evidence-based guidelines for the use of aripiprazole for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? KEY FINDINGS Three systematic reviews with meta-analyses, two randomized controlled trials, and two evidence-based guidelines were identified regarding the use of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments. METHODS A limited literature search was conducted on key resources including PubMed, Ovid PsychINFO, Ovid Embase, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were used to limit retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and April 29, 2016. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada.
    [Show full text]
  • 12 Retina Gabriele K
    299 12 Retina Gabriele K. Lang and Gerhard K. Lang 12.1 Basic Knowledge The retina is the innermost of three successive layers of the globe. It comprises two parts: ❖ A photoreceptive part (pars optica retinae), comprising the first nine of the 10 layers listed below. ❖ A nonreceptive part (pars caeca retinae) forming the epithelium of the cil- iary body and iris. The pars optica retinae merges with the pars ceca retinae at the ora serrata. Embryology: The retina develops from a diverticulum of the forebrain (proen- cephalon). Optic vesicles develop which then invaginate to form a double- walled bowl, the optic cup. The outer wall becomes the pigment epithelium, and the inner wall later differentiates into the nine layers of the retina. The retina remains linked to the forebrain throughout life through a structure known as the retinohypothalamic tract. Thickness of the retina (Fig. 12.1) Layers of the retina: Moving inward along the path of incident light, the individual layers of the retina are as follows (Fig. 12.2): 1. Inner limiting membrane (glial cell fibers separating the retina from the vitreous body). 2. Layer of optic nerve fibers (axons of the third neuron). 3. Layer of ganglion cells (cell nuclei of the multipolar ganglion cells of the third neuron; “data acquisition system”). 4. Inner plexiform layer (synapses between the axons of the second neuron and dendrites of the third neuron). 5. Inner nuclear layer (cell nuclei of the bipolar nerve cells of the second neuron, horizontal cells, and amacrine cells). 6. Outer plexiform layer (synapses between the axons of the first neuron and dendrites of the second neuron).
    [Show full text]
  • Localisation of Visual Hallucinations
    BRITISH MEDICAL JOURNAL 16 JULY 1977 147 of hypothermia; the duration of cardiac arrest; and the disturbances of sleep or consciousness.4 Hallucinations may be promptness and correctness of treatment. Peterson's pessi- evoked by sensory deprivation, but other factors are usually mistic report from California,8 in which all 15 near-drowned present; thus the "black-patch" delirium that may follow children who had fits, fixed dilated pupils, flaccidity, and loss cataract extraction in the elderly probably results from sensory Br Med J: first published as 10.1136/bmj.2.6080.147 on 16 July 1977. Downloaded from of pain sensation suffered severe anoxic encephalopathy, deprivation and mild senile brain changes and is more frequent may be explained by the high water temperatures there. In when hearing is also impaired.5 warm water the protective effect of hypothermia against brain Hallucinations may be due to focal lesions. Past experiences, damage would be missing. In contrast was the case described the quality of eidetic imagery, and psychodynamic "actors in Trondheim, Norway,9 in which a 5-year-old fell through influence the content of organic hallucinosis,6 and it would be ice in fresh water with an outside temperature of 10° below unwise to lean too heavily on the occurrence and nature of zero centigrade. He was in the water for 22 minutes and was hallucinosis in localising intracranial lesions. Visual hallucina- brought out apparently dead, with widely dilated pupils and tions are a relatively infrequent accompaniment oflesions ofthe bluish white skin. He was warmed up (the method was not calcarine cortex (Brodmann's area 17), which has few thalamo- described) and-despite the risks noted above-was given cortical connections; yet they may occur as a false-localising external cardiac massage without suffering ventricular symptom of frontal or subtentorial lesions.
    [Show full text]
  • Download Executive Summary
    Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Effective Health Care Program Antipsychotics medications are approved The Effective Health Care Program by the U.S. Food and Drug Administration was initiated in 2005 to provide valid (FDA) for treatment of schizophrenia and evidence about the comparative bipolar disorder. These medications are effectiveness of different medical commonly divided into two classes, interventions. The object is to help reflecting two waves of historical consumers, health care providers, and development: the conventional others in making informed choices antipsychotics and the atypical. The among treatment alternatives. Through conventional antipsychotics served as the its Comparative Effectiveness Reviews, first successful pharmacologic treatment the program supports systematic for primary psychotic disorders such as appraisals of existing scientific schizophrenia. Having been widely used evidence regarding treatments for for decades, the conventional high-priority health conditions. It also antipsychotics also produced various side promotes and generates new scientific effects requiring additional medications, evidence by identifying gaps in which spurred the development of the existing scientific evidence and atypical antipsychotics. supporting new research. The program Currently, nine atypical antipsychotic drugs puts special emphasis on translating have been approved by FDA: aripiprazole, findings into a variety of useful asenapine, clozapine, iloperidone, formats for different stakeholders, olanzapine, paliperidone, quetiapine, including consumers. risperidone, and ziprasidone. These drugs The full report and this summary are have been used off-label (i.e., for available at www.effectivehealthcare. indications not approved by FDA) for the ahrq.gov/reports/final.cfm. treatment of various psychiatric conditions.
    [Show full text]
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • Adjunctive Risperidone Treatment for Antidepressant-Resistant
    Supplementary Online Content Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant- resistant symptoms of chronic military service–related PTSD. JAMA. 2011;306(5):493-502. eTable 1. Follow-up Drugs Started After Randomization eTable 2. Baseline Medications eTable 3. Number of Different Drugs From Each Major Class Each Patient Is Taking at Baseline eTable 4. Baseline Medication Combinations eTable 5. Adverse Events eFigure 1. Product-Limit Survival Estimates With Number of Subjects at Risk eFigure 2. Percentage of Veterans at Each CAPS Severity Level at 24 Weeks, by Treatment This supplementary material has been provided by the authors to give readers additional information about their work. © 2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eTable 1. Follow-up Drugs Started After Randomization Placebo Risperidone N= 134 N= 133 Total Patients % Patients % Patients % p-value Drugs started after randomization 46 34.3 59 44.4 105 39.3 0.10 Adrenergic Drugs 4 3.0 5 3.8 9 3.4 0.75 Atenolol 0 0.0 2 1.5 2 0.7 Metoprolol 3 2.2 2 1.5 5 1.9 Propranolol 1 0.7 1 0.8 2 0.7 Opiates 22 16.4 19 14.3 41 15.4 0.73 Codeine 1 0.7 1 0.8 2 0.7 Fentanyl 3 2.2 0 0.0 3 1.1 Hydrocodone (With Or Without 13 9.7 10 7.5 23 8.6 Acetaminophen) Methadone 1 0.7 0 0.0 1 0.4 Morphine 3 2.2 2 1.5 5 1.9 Oxycodone (With Or Without 4 3.0 7 5.3 11 4.1 Acetaminophen) Tramadol 3 2.2 2 1.5 5 1.9 Psycho-Stimulants 0 0.0 2 1.5 2 0.7 0.25 Methylphenidate 0 0.0 2 1.5 2 0.7 Muscle
    [Show full text]
  • Visual Perception in Migraine: a Narrative Review
    vision Review Visual Perception in Migraine: A Narrative Review Nouchine Hadjikhani 1,2,* and Maurice Vincent 3 1 Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA 2 Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, University of Gothenburg, 41119 Gothenburg, Sweden 3 Eli Lilly and Company, Indianapolis, IN 46285, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-617-724-5625 Abstract: Migraine, the most frequent neurological ailment, affects visual processing during and between attacks. Most visual disturbances associated with migraine can be explained by increased neural hyperexcitability, as suggested by clinical, physiological and neuroimaging evidence. Here, we review how simple (e.g., patterns, color) visual functions can be affected in patients with migraine, describe the different complex manifestations of the so-called Alice in Wonderland Syndrome, and discuss how visual stimuli can trigger migraine attacks. We also reinforce the importance of a thorough, proactive examination of visual function in people with migraine. Keywords: migraine aura; vision; Alice in Wonderland Syndrome 1. Introduction Vision consumes a substantial portion of brain processing in humans. Migraine, the most frequent neurological ailment, affects vision more than any other cerebral function, both during and between attacks. Visual experiences in patients with migraine vary vastly in nature, extent and intensity, suggesting that migraine affects the central nervous system (CNS) anatomically and functionally in many different ways, thereby disrupting Citation: Hadjikhani, N.; Vincent, M. several components of visual processing. Migraine visual symptoms are simple (positive or Visual Perception in Migraine: A Narrative Review. Vision 2021, 5, 20. negative), or complex, which involve larger and more elaborate vision disturbances, such https://doi.org/10.3390/vision5020020 as the perception of fortification spectra and other illusions [1].
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Second-Generation Long-Acting Injectable Antipsychotics: a PRACTICAL GUIDE Understanding Each of These Medications’ Unique Properties Can Optimize Patient Care
    Second-generation long-acting injectable antipsychotics: A PRACTICAL GUIDE Understanding each of these medications’ unique properties can optimize patient care Brittany L. Parmentier, PharmD, MPH, here are currently 7 FDA-approved second-generation long-acting BCPS, BCPP 1-7 Clinical Assistant Professor injectable antipsychotics (LAIAs). These LAIAs provide a Department of Pharmacy Practice Tunique dosage form that allows patients to receive an antipsy- The University of Texas at Tyler Fisch College of Pharmacy chotic without taking oral medications every day, or multiple times per Tyler, Texas day. This may be an appealing option for patients and clinicians, but Disclosure The author reports no financial relationships with any because there are several types of LAIAs available, it may be difficult to companies whose products are mentioned in this article, or with determine which LAIA characteristics are best for a given patient. manufacturers of competing products. Since the FDA approved the first second-generation LAIA, risperidone long-acting injectable (LAI),1 in 2003, 6 additional second-generation LAIAs have been approved: • aripiprazole LAI • aripiprazole lauroxil LAI • olanzapine pamoate LAI • paliperidone palmitate monthly injection • paliperidone palmitate 3-month LAI • risperidone LAI for subcutaneous (SQ) injection. When discussing medication options with patients, clinicians need to consider factors that are unique to each LAIA. In this article, I describe the similarities and differences among the second-generation LAIAs, and address common questions about these medications. A major potential benefit: Increased adherence One potential benefit of all LAIAs is increased medication adherence com- pared with oral antipsychotics. One meta-analysis of 21 randomized con- trolled trials (RCTs) that compared LAIAs with oral antipsychotics and Current Psychiatry GEORGE MATTEI/SCIENCE SOURCE GEORGE MATTEI/SCIENCE Vol.
    [Show full text]
  • INVEGA SUSTENNA® (Paliperidone Palmitate)
    INVEGA SUSTENNA® INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use (paliperidone palmitate) extended-release injectable suspension, for intramuscular use --------------------------- DOSAGE FORMS AND STRENGTHS --------------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION Extended-release injectable suspension: 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, These highlights do not include all the information needed to use 156 mg/mL, or 234 mg/1.5 mL (3) INVEGA SUSTENNA® safely and effectively. See full prescribing information for INVEGA SUSTENNA®. ----------------------------------- CONTRAINDICATIONS ----------------------------------- INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable Known hypersensitivity to paliperidone, risperidone, or to any excipients in suspension, for intramuscular use INVEGA SUSTENNA®. (4) Initial U.S. Approval: 2006 -----------------------------WARNINGS AND PRECAUTIONS ----------------------------- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with WITH DEMENTIA-RELATED PSYCHOSIS Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse See full prescribing information for complete boxed warning. reactions (e.g. stroke, transient ischemic attack). (5.2) • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of Elderly patients with dementia-related psychosis treated with antipsychotic drug and close monitoring. (5.3) drugs are
    [Show full text]
  • Association of Selective Serotonin Reuptake Inhibitors with the Risk for Spontaneous Intracranial Hemorrhage
    Supplementary Online Content Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published online December 5, 2016. doi:10.1001/jamaneurol.2016.4529 eMethods 1. List of Antidepressants for Cohort Entry eMethods 2. List of Antidepressants According to the Degree of Serotonin Reuptake Inhibition eMethods 3. Potential Confounding Variables Included in Multivariate Models eMethods 4. Sensitivity Analyses eFigure. Flowchart of Incident Antidepressant (AD) Cohort Definition and Case- Control Selection eTable 1. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 2. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 3. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs. eTable 4. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 5. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 6. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods 1.
    [Show full text]
  • Localizing and Lateralizing Value of Epileptic Symptoms in Temporal Lobe Epilepsy
    Localizing and Lateralizing Value of Epileptic Symptoms in Temporal Lobe Epilepsy Jean-Marc Saint-Hilaire and Mary Anne Lee ABSTRACT: The symptoms and signs associated with all stages of a temporal lobe seizure may be helpful in determining both the localization and lateralization of seizure onset. Auras, when present, may be very suggestive of temporal lobe onset and may further localize to a mesiobasal or lateral temporal lobe site of onset. During the ictus, automatisms and motor phenomena may be highly indicative of temporal lobe seizure activity and may even help lateralize the discharge. In the post-ictal period, motor paresis and aphasia are helpful in lateralization. Video E.E.G. data has provided extensive information on the utility of ictal symptomatology in seizure localization. Thus, the seizure semiology provides important adjunctive information in evaluating patients for epilepsy surgery and should be concordant with information obtained from ictal EEG, neuroimaging and neuropsychology. RÉSUMÉ: La valeur des symptômes épileptiques pour la localisation et la latéralisation dans l'épilepsie temporale. Les symptômes et les signes associés à tous les stades d'une crise temporale peuvent aider à déterminer la localisation et la latéralisation du site de déclenchement de la crise. L'aura, quand elle est présente, peut être très suggestive d'un début temporal et peut localiser de façon plus précise le site de déclenchement de la crise. Pendant la crise, les automatismes et les phénomènes moteurs peuvent être hautement indicateurs d'une activité ictale temporale et peuvent même aider à latéraliser la décharge. Dans la période post-ictale, la parésie motrice et l'aphasie peuvent aider à la latéralisation.
    [Show full text]